Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06120140 (COCOON) for Carcinoma, Non-Small-Cell Lung is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON) Phase 2 300
Clinical Trial NCT06120140 (COCOON) is designed to study Treatment for Carcinoma, Non-Small-Cell Lung. It is a Phase 2 interventional study that is recruiting, having started on 16 February 2024, with plans to enroll 300 participants. Led by Janssen Research & Development, LLC, it is expected to complete by 31 January 2032. The latest data from ClinicalTrials.gov was last updated on 13 March 2026.
Brief Summary
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-smal...Show More
Official Title
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Conditions
Carcinoma, Non-Small-Cell LungOther Study IDs
- COCOON
- 61186372NSC2007
- 61186372NSC2007 (Other Identifier) (Janssen Research & Development, LLC)
- 2023-505863-35-00 (Registry Identifier) (EUCT number)
NCT ID Number
Start Date (Actual)
2024-02-16
Last Update Posted
2026-03-13
Completion Date (Estimated)
2032-01-31
Enrollment (Estimated)
300
Study Type
Interventional
PHASE
Phase 2
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalArm A: Enhanced Dermatologic Management Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously ...Show More | Amivantamab IV Amivantamab will be administered. Lazertinib Lazertinib tablet will be administered orally. Doxycycline Doxycycline tablet will be administered orally. Minocycline Minocycline capsule will be administered orally. Clindamycin Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer Noncomedogenic skin moisturizer will be used as topical application. |
Active ComparatorArm B: Standard-of-Care Dermatologic Management Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm. | Amivantamab IV Amivantamab will be administered. Lazertinib Lazertinib tablet will be administered orally. Chlorhexidine Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer Noncomedogenic skin moisturizer will be used as topical application. |
ExperimentalSub-study: Cohort A: Ruxolitinib Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to \[\>=\] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazert...Show More | Amivantamab IV Amivantamab will be administered. Lazertinib Lazertinib tablet will be administered orally. Doxycycline Doxycycline tablet will be administered orally. Minocycline Minocycline capsule will be administered orally. Clindamycin Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer Noncomedogenic skin moisturizer will be used as topical application. Ruxolitinib Ruxolitinib will be used to the affected skin area. |
ExperimentalSub-study: Cohort B: Tacrolimus Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade \>= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib. | Amivantamab IV Amivantamab will be administered. Lazertinib Lazertinib tablet will be administered orally. Doxycycline Doxycycline tablet will be administered orally. Minocycline Minocycline capsule will be administered orally. Clindamycin Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer Noncomedogenic skin moisturizer will be used as topical application. Tacrolimus Tacrolimus will be used as topical application to the affected skin area. |
ExperimentalAmivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as foll...Show More | Amivantamab SC Amivantamab will be administered as SC injection. Lazertinib Lazertinib tablet will be administered orally. Doxycycline Doxycycline tablet will be administered orally. Minocycline Minocycline capsule will be administered orally. Chlorhexidine Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer Noncomedogenic skin moisturizer will be used as topical application. Ruxolitinib Ruxolitinib will be used to the affected skin area. Zinc gluconate Zinc gluconate tablet will be administered. Propranolol Propranolol tablet will be administered. Timolol Timolol will be used to the affected skin area. Clobetasol Clobetasol shampoo will be used on the scalp. |
ExperimentalAmivantamab SC Expansion Cohort: Modified Schedule Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp ...Show More | Amivantamab SC Amivantamab will be administered as SC injection. Lazertinib Lazertinib tablet will be administered orally. Doxycycline Doxycycline tablet will be administered orally. Minocycline Minocycline capsule will be administered orally. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment | Number of participants with Grade \>= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 weeks after initiation of anticancer treatment |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0 | Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 12 weeks after initiation of anticancer treatment |
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0 | Number of participants with Grade \>=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. | Up to 6 months after initiation of anticancer treatment |
Number of Grade >= 2 DAEI Per Participants | Number of grade \>= 2 DAEI per participants will be reported. | Up to 12 months |
Time to First Occurrence of Grade >=2 DAEI | Time to first occurrence of Grade \>=2 DAEI will be reported. | Up to 12 months |
Time to Resolution of Grade >= 2 DAEI | Time to resolution of Grade \>= 2 DAEI will be reported. | Up to 12 months |
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0 | Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 6 months after initiation of anticancer treatment |
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0 | Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported. | Up to 12 months after initiation of anticancer treatment |
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months | Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions. | Baseline, up to Month 12 |
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months | Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale. | Baseline, up to Month 12 |
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months | Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. | Baseline, up to Month 12 |
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only) | The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 \[no limitation\] to 4 \[incapacity\]). | Baseline, up to Month 12 |
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs | Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported. | Up to 12 months |
Relative Dose Intensity (RDI) of Anticancer Treatment | Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose. | Up to 12 months |
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0 | Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. | Up to 12 months |
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0 | Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. | Up to 12 months |
Progression Free Survival (PFS) | PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first. | Up to 12 months |
Overall Response Rate (ORR) | ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator. | Up to 12 months |
Duration of Response (DoR) | DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria. | Up to 12 months |
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment | Participants with Grade \>= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 weeks after initiation of anticancer treatment |
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention | Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 months |
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention | Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. | Up to 12 months |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
- Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
- A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
- Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
- Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care \[SoC\]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)
- History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \[participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment\] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
- Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
- Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
- Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
- Participant has an active or past medical history of leptomeningeal disease
- Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)
Janssen Research & Development, LLCStudy Central Contact
Contact: Study Contact, 844-434-4210, [email protected]
93 Study Locations in 11 Countries
Arizona
Ironwood Cancer and Research Center, Chandler, Arizona, 85224, United States
Recruiting
California
City of Hope, Duarte, California, 91010, United States
Recruiting
Providence Fullerton, Fullerton, California, 92835, United States
Recruiting
Los Angeles Cancer Network, Glendale, California, 91204, United States
Recruiting
City of Hope Seacliff, Huntington Beach, California, 92648, United States
Recruiting
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, 92618, United States
Recruiting
City of Hope Long Beach Elm, Long Beach, California, 90813, United States
Recruiting
Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States
Recruiting
Keck Hospital of USC, Los Angeles, California, 90033, United States
Recruiting
USC Norris Oncology Hematology Newport Beach, Newport Beach, California, 92663, United States
Recruiting
Kaiser Permanente Oakland Medical Center, Oakland, California, 94611, United States
Recruiting
Kaiser Permanente Roseville Medical Center, Roseville, California, 95661, United States
Recruiting
Kaiser Permanente San Francisco Medical Center, San Francisco, California, 94115, United States
Recruiting
Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, 95051, United States
Recruiting
City of Hope South Pasadena, South Pasadena, California, 91030, United States
Recruiting
Kaiser Permanente Northern California, Vallejo, California, 94589, United States
Recruiting
Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, California, 94596, United States
Recruiting
Georgia
University Cancer & Blood Center, Athens, Georgia, 30607, United States
Recruiting
Illinois
Hope and Healing Care, Hinsdale, Illinois, 60521, United States
Recruiting
Missouri
Oncology Hematology Associates, Springfield, Missouri, 65807, United States
Recruiting
Nevada
Renown Health Medical Oncology, Reno, Nevada, 89502, United States
Recruiting
New Jersey
Hunterdon Hematology Oncology, Flemington, New Jersey, 08822, United States
Completed
New York
Clinical Research Alliance Inc, Westbury, New York, 11590, United States
Completed
North Carolina
Regional Medical Oncology Center, Wilson, North Carolina, 27893, United States
Recruiting
Ohio
University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States
Recruiting
Virginia
Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States
Recruiting
Washington
Valley Medical Center, Renton, Washington, 98055, United States
Completed
Wisconsin
Gundersen Health System, West Salem, Wisconsin, 54669, United States
Recruiting
Hospital Italiano de Buenos Aires, Buenos Aires, C1199, Argentina
Recruiting
IADT Instituto Argentino de Diagnostico y Tratamiento, CABA, C1122, Argentina
Recruiting
Centro Medico Austral, Capital Federal, C1017, Argentina
Recruiting
Hospital Italiano de La Plata, La Plata, B1900AXI, Argentina
Completed
Hospital Privado de la Comunidad, Mar del Plata, B7602, Argentina
Recruiting
CTO Centro De Tratamento Oncologico LTDA, Belém, 66.073-005, Brazil
Recruiting
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, 30150-221, Brazil
Recruiting
Liga Paranaense de Combate ao Cancer, Curitiba, 81520-060, Brazil
Recruiting
Fundacao Doutor Amaral Carvalho, Jaú, 17.210-080, Brazil
Recruiting
Hospital Nossa Senhora da Conceicao S A, Porto Alegre, 91350 200, Brazil
Recruiting
Nucleo de Oncologia da Bahia Oncoclinicas, Salvador, 40170 070, Brazil
Recruiting
Hospital Ana Nery Santa Cruz do Sul, Santa Cruz do Sul, 96835-100, Brazil
Recruiting
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, São Paulo, 01246 000, Brazil
Recruiting
Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, 01509 900, Brazil
Recruiting
Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate, Taubaté, 12030-200, Brazil
Recruiting
Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia, Vitória, 29043-260, Brazil
Recruiting
Changzhou No 2 Peoples Hospital, Changzhou, 213004, China
Recruiting
West China Hospital, Chengdoucun, 610041, China
Recruiting
Sichuan Cancer Hospital, Chengdu, 610041, China
Recruiting
The First Affiliated Hospital Sun Yat sen University, Guangzhou, 510080, China
Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310003, China
Recruiting
Harbin medical university cancer hospital, Harbin, 150040, China
Recruiting
Huizhou Municipal Central Hospital, Huizhou, 516001, China
Recruiting
Zhongda Hospital Southeast University, Nanjing, 210000, China
Recruiting
Fudan University Shanghai Cancer Center, Shanghai, 200032, China
Recruiting
The First Affiliated Hospital of Xian Jiaotong University, Xi'an, 710061, China
Recruiting
Henan Cancer Hospital, Zhengzhou, 450008, China
Recruiting
Hopital Nord, Marseille, 13915, France
Recruiting
Hopital PASTEUR, Nice, 06001, France
Recruiting
Institut Curie, Paris, 75005, France
Recruiting
Universitaetsklinikum der RWTH Aachen, Aachen, 52074, Germany
Recruiting
Kliniken Essen-Mitte, Essen, 45136, Germany
Recruiting
Universitaetsklinikum Giessen und Marburg GmbH, Giessen, 35392, Germany
Recruiting
Thoraxklinik am Universitatsklinikum Heidelberg, Heidelberg, 69126, Germany
Recruiting
Klinikum Kassel GmbH, Kassel, 34125, Germany
Recruiting
Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, 24105, Germany
Recruiting
Hospital Pulau Pinang, George Town, 10450, Malaysia
Recruiting
University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia
Recruiting
Hospital Tengku Ampuan Afzan, Kuantan, 25100, Malaysia
Recruiting
Hospital Umum Sarawak, Kuching, 93586, Malaysia
Recruiting
Chungbuk National University Hospital, Cheongju-si, 28644, South Korea
Recruiting
Gachon University Gil Medical Center, Incheon, 21565, South Korea
Recruiting
Severance Hospital Yonsei University Health System, Seoul, 03722, South Korea
Recruiting
Hosp Univ A Coruna, A Coruña, 15006, Spain
Recruiting
Hosp. Gral. Univ. de Alicante, Alicante, 03010, Spain
Recruiting
Hosp. Univ. Quiron Dexeus, Barcelona, 08028, Spain
Recruiting
Hosp Univ Vall D Hebron, Barcelona, 08035, Spain
Recruiting
Hosp. Univ. de Jaen, Jaén, 23007, Spain
Recruiting
Hosp. Univ. Lucus Augusti, Lugo, 27003, Spain
Recruiting
Hosp. Gral. Univ. Gregorio Maranon, Madrid, 28007, Spain
Recruiting
Hosp Regional Univ de Malaga, Málaga, 29010, Spain
Recruiting
Hosp. Ntra. Sra. de Valme, Seville, 41014, Spain
Recruiting
Chang Gung Memorial Hospital, Kaohsiung City, 833, Taiwan
Recruiting
Taichung Veterans General Hospital, Taichung, 40705, Taiwan
Recruiting
National Taiwan University Hospital, Taipei, 100, Taiwan
Recruiting
Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan
Recruiting
National Taiwan University Hospital Hsin Chu Branch, Taoyuan District, 30059, Taiwan
Recruiting
Adana City Hospital, Adana, 1060, Turkey (Türkiye)
Recruiting
Gulhane Training and Research Hospital, Ankara, 06010, Turkey (Türkiye)
Recruiting
Gazi University Hospital, Ankara, 06560, Turkey (Türkiye)
Recruiting
Ankara Bilkent City Hospital, Ankara, 6800, Turkey (Türkiye)
Recruiting
Bakirkoy Training and Research Hospital, Istanbul, 34147, Turkey (Türkiye)
Recruiting
I A U VM Medical Park Florya Hastanesi, Istanbul, 34295, Turkey (Türkiye)
Recruiting
Ege University Medical Faculty, Izmir, 35100, Turkey (Türkiye)
Recruiting
Ondokuz Mayis University, Samsun, 55420, Turkey (Türkiye)
Recruiting